UttamKeshavRaoMDMBA
Internal Medicine • Austin, TXHematology/Oncology
Transplant/cellular therapy, malignant hematology
Dr. Rao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
901 W Ben White Boulevard Frontage Rd
777 Preston Research Building
Austin, TX 78704
Education & Training
Vanderbilt University Medical CenterHematopoietic Cell Transplantation, 2021 - 2022
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
University of Alabama Medical CenterResidency, Internal Medicine, 2015 - 2018
Tulane University School of MedicineClass of 2015
Certifications & Licensure
TX State Medical License 2022 - 2026
AL State Medical License 2017 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 24 citationsAutologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio C. Chavez, Yago Nieto
Blood Advances. 2021-03-23 - 53 citationsAllogeneic transplantation after PD-1 blockade for classic Hodgkin lymphomaReid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini
Leukemia. 2021-03-03 - 2 citationsPredicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 ...Uttam Rao, Brian G. Engelhardt
Clinical Hematology International. 2020-05-21
Abstracts/Posters
- Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin LymphomaUttam Rao, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...Uttam Rao, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
